Spironolactone için Androgenetik Alopesi

25 çalışmaya (4 meta-analyses, 2 RCTs), toplam 6,273 katılımcıyla dayanmaktadır. 19/25 çalışma olumlu etkiler göstermektedir.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

Sonuç

Spironolactone is well-supported by research as an anti-androgen medication that may help reduce hair loss in androgenetic alopecia, particularly in women, though it requires medical supervision.

76% of studies show positive effects, backed by 4 meta-analyses
Works by blocking androgen hormones that contribute to hair miniaturization
Particularly studied in women with PCOS-related and female pattern hair loss
Requires prescription and medical monitoring due to hormonal effects

Key Study Findings

Review

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.

Dose: None vs: None Outcome: None Etki: None None

Popülasyon: women with androgenetic alopecia (female pattern hair loss)

Review

Male and female pattern hair loss.

Dose: None vs: Placebo Etki: None None

RCT n=48 24 weeks Double-blind

Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …

Dose: Spironolactone 100 mg once daily vs: Placebo Etki: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp p=0.063 (terminal hair counts)

Randomized Controlled Trial n=125 4 weeks Double-blind

Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, …

Dose: CBD 300 mg + 1 mg each of 8 terpenes vs: Placebo Outcome: Percentage of time in SWS + REM sleep Etki: 1.3% increase [0.1-2.5%]; up to 48 min/night in su 0.03

Popülasyon: Individuals with insomnia

Cohort Study n=203

An international multicenter, retrospective cohort study of 203 patients with pediatric androgenetic alopecia.

Dose: None vs: None Outcome: Clinical presentation and treatment outcomes in pediatric AGA Etki: None None

Popülasyon: Pediatric patients with androgenetic alopecia (multicenter)

Randomized Controlled Trial n=30

A Prospective and Comparative Study to Explore the Effects of Platelet-Rich Plasma in Hair Transplantation …

Dose: None vs: Drug therapy (minoxidil + finasteride/spironolactone) only Outcome: Follicle survival rate, growth rate, hair strength Etki: None None

Popülasyon: Patients with androgenetic alopecia

Key Statistics

Çalışmalar

6472

Katılımcılar

↑

Positive

Derece

Referenced Papers

Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments. Review

American journal of … 2026

Efficacy, safety and tolerability of drugs for alopecia: a comprehensive review. Review

Expert opinion on … 2025 11 atıf

Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. RCT

The British journal … 2025 10 atıf

Epidemiological landscape of androgenetic alopecia in the US: An All of Us cross-sectional study. Other

PloS one 2025 8 atıf

A Scoping Review of Exosome Delivery Applications in Hair Loss. Review

Cureus 2025 7 atıf

Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, crossover study. RCT

Journal of clinical … 2025 6 atıf

A Prospective and Comparative Study to Explore the Effects of Platelet-Rich Plasma in Hair Transplantation for Patients With Androgenetic Alopecia. RCT

Journal of cosmetic … 2025 5 atıf

Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a randomized, double-blind, placebo-controlled, parallel-group pilot … Other

International journal of … 2025 3 atıf

An international multicenter, retrospective cohort study of 203 patients with pediatric androgenetic alopecia. Other

Journal of the … 2025 3 atıf

Non-classical congenital adrenal hyperplasia: current insights into clinical implications, diagnosis and treatment. Review

Endocrine 2025 2 atıf

Male and female pattern hair loss. Review

Australian prescriber 2025 2 atıf

Estrogen hormone therapy stabilizes lateral hairline in transfeminine patients: Implications for facial feminization surgery. Other

Journal of plastic, … 2025 1 atıf

Evaluating the Role of the Gabrin Sign in Predicting COVID-19 Severity Among Patients with Androgenic Alopecia. Other

International journal of … 2025

The Hormonal Background of Hair Loss in Non-Scarring Alopecias. Review

Biomedicines 2024 17 atıf

The efficacy of the combination of topical minoxidil and oral spironolactone compared with the combination of topical minoxidil and oral … RCT

Journal of cosmetic … 2024 14 atıf

Management of androgenic alopecia: a systematic review of the literature. Systematic Review

Journal of cosmetic … 2024 11 atıf

Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies. Review

Journal of clinical … 2024 11 atıf

Cannabidiol (CBD) Inhibits Foam Cell Formation via Regulating Cholesterol Homeostasis and Lipid Metabolism. Other

Molecular nutrition & … 2024 5 atıf

Comparative analysis of low-dose oral minoxidil with spironolactone versus finasteride or dutasteride in female androgenetic alopecia management. Other

Archives of dermatological … 2024 4 atıf

Improving efficacy and maintaining safety in the treatment of alopecia with low-dose oral minoxidil and spironolactone combination therapy: A retrospective … Other

JAAD international 2024 1 atıf

Potential of dietary hemp and cannabinoids to modulate immune response to enhance health and performance in animals: opportunities and challenges. Review

Frontiers in immunology 2023 99 atıf

Androgenetic alopecia: An update. Review

JAAD international 2023 80 atıf

Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs. Review

Clinical, cosmetic and … 2023 58 atıf

The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review. Review

Clinical, cosmetic and … 2023 25 atıf

Androgenetic alopecia in transgender and gender diverse populations: A review of therapeutics. Review

Journal of the … 2023 24 atıf

Medical and procedural treatment of androgenetic alopecia - Where are we? Review

Journal of the … 2023 20 atıf

The Efficacy and Safety of Oral Spironolactone in the Treatment of Female Pattern Hair Loss: A Systematic Review and Meta-Analysis. Review

Cureus 2023 13 atıf

Efficacy and safety profile of oral spironolactone use for androgenic alopecia: A systematic review. Systematic Review

Journal of the … 2022 24 atıf

Efficacy and Safety of 5% Minoxidil Alone, Minoxidil Plus Oral Spironolactone, and Minoxidil Plus Microneedling on Female Pattern Hair Loss: … Case Report

Frontiers in medicine 2022 14 atıf

Primary care provider attitudes, experiences and practices about cannabidiol (CBD) and barriers to patient-provider communication about CBD use: A qualitative … Other

PEC innovation 2022 11 atıf

Observation on the Efficacy of a Combined Treatment for Moderate and Severe Androgenetic Alopecia Incorporating Electric Microneedles. Other

Clinical, cosmetic and … 2022 3 atıf

The Role of Cannabidiol (CBD) in Chronic Pain Management: An Assessment of Current Evidence. Review

Current pain and … 2020 85 atıf

Spironolactone use does not increase the risk of female breast cancer recurrence: A retrospective analysis. Other

Journal of the … 2020 19 atıf

Herbal Medicines For Treatment of Androgenic Alopecia. Review

Alternative therapies in … 2020 11 atıf

Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. Meta-Analysis

The Journal of … 2019 101 atıf

Androgens in women: Androgen-mediated skin disease and patient evaluation. Review

Journal of the … 2019 95 atıf

Androgens in women: Hormone-modulating therapies for skin disease. Review

Journal of the … 2019 55 atıf

Methods of treatment patients with androgenetic alopecia based on reference of Department of Dermatology in Cracow. Other

Polski merkuriusz lekarski … 2019 4 atıf

Female pattern hair loss: A clinical, pathophysiologic, and therapeutic review. Review

International journal of … 2018 129 atıf

Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study. Other

Actas dermo-sifiliograficas 2018 9 atıf

Androgenic alopecia: an entity to consider in adolescence. Case Report

BMJ case reports 2017 6 atıf

Interventions for female pattern hair loss. Meta-Analysis

The Cochrane database … 2016 18 atıf

Selected Disorders of Skin Appendages--Acne, Alopecia, Hyperhidrosis. Review

The Medical clinics … 2015 66 atıf

Evidence-based approach to cutaneous hyperandrogenism in women. Review

Journal of the … 2015 50 atıf

Female pattern hair loss. Review

Current problems in … 2015 8 atıf

Follicular delivery of spironolactone via nanostructured lipid carriers for management of alopecia. Other

International journal of … 2014 113 atıf

Female pattern alopecia: current perspectives. Review

International journal of … 2013

Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Review

The British journal … 2011 96 atıf

Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Other

Dermatologic clinics 2010 80 atıf

Hormonal therapy for acne: why not as first line therapy? facts and controversies. Review

Clinics in dermatology 2010

Hair loss in women. Review

Seminars in cutaneous … 2009 4 atıf

A review of hormonal therapy for female pattern (androgenic) alopecia. Review

Dermatology online journal 2008

Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Case Report

The Australasian journal … 2007 32 atıf

Association of androgenetic alopecia and hypertension. Other

European journal of … 2007

[Androgenetic alopecia]. Review

Revue medicale de … 2004

Practical recommendations for the use of ACE inhibitors, beta-blockers and spironolactone in heart failure: putting guidelines into practice. Other

European journal of … 2001 67 atıf

Current aspects of antiandrogen therapy in women. Review

Current pharmaceutical design 1999

Management of androgenetic alopecia. Review

Journal of the … 1999

Hair regrowth. Therapeutic agents. Review

Dermatologic clinics 1998 121 atıf

Beneficial effect of spironolactone on androgenic alopecia. Other

Clinical endocrinology 1997

Treatment of androgenic disorders with dexamethasone: dose-response relationship for suppression of dehydroepiandrosterone sulfate. Other

Journal of the … 1990

Oral spironolactone therapy for female patients with acne, hirsutism or androgenic alopecia. Other

The British journal … 1985

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

hairloss:: 100-200 mg/day (prescription)

Üst sınır: 200 mg/day (hair loss indication)

Araştırmalarda İncelenen Dozajlar

Dozaj	Süre	Etki	N
None	--	Neutral	--
None	--	Positive	--
Spironolactone 100 mg once daily	24 weeks	Positive	48
CBD 300 mg + 1 mg each of 8 terpenes	4 weeks	Positive	125
None	--	Positive	203
None	--	Positive	30
various across included studies (2015-2024)	--	Positive	--
None	--	Mixed	--

En iyi alım zamanı: Once or twice daily with food; prescription required

Safety & Side Effects

Bildirilen Yan Etkiler

⚠ Menstrual irregularities
⚠ Breast tenderness
⚠ Hyperkalemia (elevated potassium levels)
⚠ Dizziness and orthostatic hypotension
⚠ Frequent urination

Bilinen Etkileşimler

● ACE inhibitors and ARBs (increased hyperkalemia risk)
● Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
● NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
● Digoxin (spironolactone may increase digoxin levels)

Tolere edilebilir üst alım: 200 mg/day (hair loss indication)

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Spironolactone help with Androgenetik Alopesi?

Based on 45 studies with 6,472 participants, there is strong evidence from multiple clinical trials that Spironolactone may support Androgenetik Alopesi management. Our evidence grade is A (Strong Evidence).

How much Spironolactone should I take for Androgenetik Alopesi?

Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Spironolactone?

Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Spironolactone and Androgenetik Alopesi?

We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,472 total participants. The overall direction of effect is positive.

Related Evidence

Şu durum için diğer içerikler: Androgenetik Alopesi

Minoxidil A Finasteride A PRP Tedavisi A Dutasteride A Omega-3 Yağ Asitleri A Mikroiğneleme A

Spironolactone diğer sağlık durumları için

Kadın Tipi Saç Dökülmesi A

Hızlı Değerlendirme

25 çalışmaya (4 meta-analyses, 2 RCTs), toplam 6,273 katılımcıyla dayanmaktadır. 19/25 çalışma olumlu etkiler göstermektedir.

Evidence Strength92%

High confidence

Çalışma Dağılımı

RCT (4)Meta (2)Other (39)

Alternatifleri Karşılaştır

Bu durum için diğer bileşenlerin nasıl karşılaştırıldığını görün.Diğer içeriklerin bu sağlık durumu için nasıl karşılaştırıldığını görün.

Şu durum için tüm içerikleri görüntüle: Androgenetik Alopesi

Daha Fazla Bilgi

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.